Recent 8-K filings for NTRB

• April 7, 2026, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband selects brand name for abuse-deterrent fentanyl patch; will submit to FDA

  Selected commercial worldwide brand name candidate for lead product, a fentanyl transdermal system with abuse-deterrent technology.

• February 13, 2026, 6:59 PM ET other material materiality 0.70 negative item 7.01item 9.01

  Nutriband terminates sale of Pocono Pharmaceuticals to Earth Vision Bio due to buyer default

  Board approved immediate termination of Pocono Pharmaceuticals sale to Earth Vision Bio Inc.

• December 30, 2025, 6:59 PM ET M&A materiality 0.75 positive item 7.01item 9.01

  Nutriband sells 90% stake in Pocono Pharma for $5M to EarthVision Bio; retains 10%

  Agreement to sell 90% interest in subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio.

• October 28, 2025, 7:59 PM ET regulatory materiality 0.75 positive item 7.01item 9.01

  Nutriband receives FDA feedback on AVERSA FENTANYL CMC plans; regulatory pathway confirmed as 505(b)(2)

  FDA meeting held September 18, 2025; final minutes received; feedback on CMC, registration batch, and stability plans.

• February 13, 2025, 6:59 PM ET other material materiality 0.60 positive item 7.01item 9.01

  Nutriband formalizes exclusive Aversa Fentanyl partnership with Kindeva; potential $80-200M US sales

  Signed addendum formalizing exclusive development partnership for Aversa Fentanyl with Kindeva Drug Delivery.

• February 12, 2025, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband receives USPTO Notice of Allowance for Aversa abuse deterrent patent

  Notice of Allowance received Feb 3, 2025 for patent app 18/369,241 covering Aversa abuse deterrent transdermal systems.

• September 18, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Nutriband announces $1 million share repurchase program; reaffirms AVERSA Fentanyl NDA timeline

  Share buyback program authorizes repurchase of up to $1,000,000 of common stock.

• April 23, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 9.01 ◈ Material Agreements

  Nutriband raises $8.4M in Regulation S equity offering of units with warrants

  Offered 2.1M units at $4.00 each, each unit comprising one common share and warrant to buy two shares.

• January 11, 2024, 6:59 PM ET other material materiality 0.80 positive item 7.01item 9.01

  Nutriband signs commercial development & clinical supply agreement with Kindeva for Aversa Fentanyl patch

  Kindeva to perform commercial process development & supply clinical materials for FDA abuse liability study.

Executive changes

Materiality & sentiment trend

Max materiality 0.80 · Median 0.55 · Most common event other_material

9 positive 1 negative 13 neutral

source · NTRB on sec.gov